Lacutamab

ASCO 2016: Phase I study protocol investigating IPH4102 in cutaneous T-cell lymphomas

June 5, 2016

Phase I study of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas commenced in November 2015 and continues on track in EU and US centers Innate Pharma SA (the “Company” -...

First patient dosed in Phase I trial of IPH4102

December 3, 2015

Proprietary, new cytotoxic anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL); Orphan drug designation in the European Union; Innate’s third first-in...

Presentation of IPH4102 rationale and phase I design at the cutaneous lymphoma task force meeting of the EORTC

September 26, 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co-discoverer...

Presentation of IPH4102 rationale and Phase I protocol to be presented at the upcoming EORTC cutaneous lymphoma task force meeting

September 7, 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis Hospital in Paris and co...

IPH 4102 preclinical data published in “cancer research”

November 3, 2014

IPH4102 is a first-in-class anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL). Phase I trial is expected to start in 2015 IPH4102 shows potent...

Orphan drug designation in the European Union for IPH4102

August 27, 2014

IPH4102 is a first-in-class anti-KIR3DL2 antibody Phase I is expected to start in 2015 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...

6th T-Cell Lymphoma Forum

January 22, 2014

Launch of IND-Enabling studies for IPH4102

November 8, 2013

IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor specifically expressed by some rare forms of cancer It is developed in an orphan disease, cutaneous T-cell lymphomas, and...

Innate Pharma presents new data for proprietary programs targeting TLR3 and KIR3DL2

April 12, 2013

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today that new preclinical data for...

What is lacutamab?

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL).

European Medicines Agency (EMA) granted PRIME designation in November 2020 to lacutamab for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.

Read more about Lacutamab